There are currently 1574 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to EvaLuate the EffIcacy and Safety of AbeLacimab in High-risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AntiCoagulation (LILAC-TIMI 76)
Recruiting
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/26/2025
Locations: Anthos Investigative Site 1039, Baltimore, Maryland
Conditions: Atrial Fibrillation (AF)
Surveillance Vs. Endoscopic Therapy for Barrett's Esophagus with Low-grade Dysplasia
Recruiting
The purpose of this study is to learn the best approach to treating patients with known or suspected Barrett's esophagus by comparing endoscopic surveillance to endoscopic eradication therapy. To diagnose and manage Barrett's esophagus and low-grade dysplasia, doctors commonly use procedures called endoscopic surveillance and endoscopic eradication therapy. Endoscopic surveillance is a type of procedure where a physician will run a tube with a light and a camera on the end of it down the patien... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
02/26/2025
Locations: Johns Hopkins Universtiy, Baltimore, Maryland
Conditions: Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Recruiting
The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membran... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Alagille Syndrome
First in Human Study of AZD9592 in Solid Tumors
Recruiting
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Research Site, Baltimore, Maryland +1 locations
Conditions: Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Recruiting
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Research Site, Baltimore, Maryland
Conditions: Advanced Solid Tumors That Are MTAP Deficient
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition
Recruiting
This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/26/2025
Locations: Mercy Medical Center, Baltimore, Maryland
Conditions: Non-alcoholic Steatohepatitis (NASH), Metabolic Dysfunction Associated Steatohepatitis (MASH)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Recruiting
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androg... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
02/26/2025
Locations: University of Maryland Medical Ctr, Baltimore, Maryland +1 locations
Conditions: Oligometastatic Prostate Cancer (OMPC)
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/26/2025
Locations: Pharmasite Research, Inc. ( Site 0167), Baltimore, Maryland
Conditions: Alzheimer Disease, Dementia
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
Recruiting
Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. This study will evaluate the efficacy, safety and tolerability of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in children \<18 years of age. Approximately 140 participants will enter CP at approximately 46 sites in locations including but not limited to Europe and North America for this study. Treatme... Read More
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
02/26/2025
Locations: Research Site, Baltimore, Maryland
Conditions: Hyperkalaemia
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Recruiting
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
02/26/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Glioma
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Recruiting
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland
Conditions: Non-small Cell Lung Cancer
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/26/2025
Locations: University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland
Conditions: Progressive Pulmonary Fibrosis